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Available online 6 January 2015Tuberculosis (TB), the infectious disease caused by the bacteriumMycobacterium tuberculosis
(MTB), remains a significant global public health threat. TB is the worldwide leading cause
of death from a bacterial disease and the second leading cause of death from an infectious
disease after Human Immunodeficiency Virus (HIV) infections. Drug-Resistant TB (DRTB) is
a growing concern around the world, but the magnitude of the disease burden is not well
defined. A series of workshops (Program Chair, G.H. Cassell) was held by the Institute of
Medicine (IOM) of the National Academy of Sciences in the United States of America in
2008 and, subsequently, in 2010–2013 in four of the highest burden countries (South Africa,
Russia, India and China) to assess the reality of the challenge of DRTB and the gaps in
knowledge required to address the threat. The issues discussed ranged from biology, epide-
miology and surveillance to diagnosis, treatment and infection control, as well as the drug
supply chain and the needs of vulnerable populations. Through these meetings, a new
image has emerged that dictates dramatic and radical policy changes in the approach to
TB if policy makers are to prevent TB from becoming once again an incurable disease.
The findings were similar in each country and were equally concerning: (1) the magnitude
of the problem of multi-drug and extensively-drug resistant TB is underestimated; (2) the
number of patients receiving treatment is small and ineffective; (3) over 90% of patients
are treated without drug susceptibility data; and (4) drug-resistant strains are spread from
human to human far more commonly than previously appreciated. To date, programs have
largely been based on an approach that emphasizes treatment of drug-sensitive cases. If
these programs provided comprehensive care for both drug-sensitive and drug-resistant
TB, this would be encompassing the entire TB epidemic and would be addressing the grow-
ing threat of the unchecked growth of resistant strains. In the current presentation, Dr. Gail
Cassell, chair of the planning committee convening the IOM workshops, will present the
themes, challenges and opportunities emerging from the IOM initiative and discuss poten-
tial global actions and next steps to combat DRTB.
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